Artemis Investment Management LLP lowered its holdings in shares of Veracyte, Inc. (NASDAQ:VCYT – Free Report) by 38.7% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 10,050 shares of the biotechnology company’s stock after selling 6,342 shares during the quarter. Artemis Investment Management LLP’s holdings in Veracyte were worth $223,000 as of its most recent SEC filing.
A number of other large investors also recently bought and sold shares of VCYT. Norges Bank purchased a new position in Veracyte during the 4th quarter valued at $11,190,000. AEGON ASSET MANAGEMENT UK Plc purchased a new position in Veracyte during the 4th quarter valued at $9,586,000. Northern Trust Corp boosted its holdings in Veracyte by 38.0% during the 3rd quarter. Northern Trust Corp now owns 982,328 shares of the biotechnology company’s stock valued at $21,935,000 after acquiring an additional 270,531 shares during the period. GW&K Investment Management LLC boosted its holdings in Veracyte by 14.9% during the 4th quarter. GW&K Investment Management LLC now owns 1,415,237 shares of the biotechnology company’s stock valued at $38,933,000 after acquiring an additional 183,616 shares during the period. Finally, Vestmark Advisory Solutions Inc. bought a new stake in Veracyte during the 4th quarter valued at $4,850,000.
Insider Transactions at Veracyte
In related news, Director Muna Bhanji sold 3,870 shares of the business’s stock in a transaction on Monday, June 10th. The stock was sold at an average price of $20.32, for a total transaction of $78,638.40. Following the transaction, the director now directly owns 23,105 shares in the company, valued at approximately $469,493.60. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. In related news, Director Karin Eastham sold 10,000 shares of the business’s stock in a transaction on Monday, April 1st. The stock was sold at an average price of $21.65, for a total transaction of $216,500.00. Following the transaction, the director now directly owns 33,125 shares in the company, valued at approximately $717,156.25. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Muna Bhanji sold 3,870 shares of the business’s stock in a transaction on Monday, June 10th. The stock was sold at an average price of $20.32, for a total value of $78,638.40. Following the transaction, the director now owns 23,105 shares in the company, valued at $469,493.60. The disclosure for this sale can be found here. In the last three months, insiders sold 17,909 shares of company stock valued at $379,882. Corporate insiders own 1.30% of the company’s stock.
Veracyte Trading Down 1.5 %
Veracyte (NASDAQ:VCYT – Get Free Report) last released its quarterly earnings results on Tuesday, May 7th. The biotechnology company reported ($0.02) EPS for the quarter, topping the consensus estimate of ($0.19) by $0.17. The firm had revenue of $96.84 million during the quarter, compared to analyst estimates of $93.35 million. Veracyte had a negative return on equity of 1.42% and a negative net margin of 18.16%. The business’s revenue for the quarter was up 17.5% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.11) EPS. Analysts forecast that Veracyte, Inc. will post -0.05 earnings per share for the current year.
Analyst Ratings Changes
VCYT has been the subject of a number of research analyst reports. The Goldman Sachs Group decreased their target price on Veracyte from $32.00 to $28.00 and set a “buy” rating for the company in a research report on Monday, April 15th. Needham & Company LLC decreased their target price on Veracyte from $33.00 to $27.00 and set a “buy” rating for the company in a research report on Wednesday, May 8th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $27.50.
Get Our Latest Analysis on VCYT
Veracyte Company Profile
Veracyte, Inc operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Nasal Swab Test for lung cancer diagnosis; and Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis.
Read More
- Five stocks we like better than Veracyte
- 3 Monster Growth Stocks to Buy Now
- Qualcomm Stock: AI-Powered Growth Despite Volatility
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- Salesforce Stock: Meeting Recap, AI Focus, and Forecast
- The Most Important Warren Buffett Stock for Investors: His Own
- Is CAVA Overextended? A Closer Look at This High-Flying Stock
Want to see what other hedge funds are holding VCYT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Veracyte, Inc. (NASDAQ:VCYT – Free Report).
Receive News & Ratings for Veracyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veracyte and related companies with MarketBeat.com's FREE daily email newsletter.